Appointment of Co-chairman

Embargoed: 0700hrs 15 August 2014

Akers Biosciences, Inc.

Akers appoints Thomas J. Knox as Co-chairman of the Board

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce the appointment of Thomas J. Knox as Non-executive Co-chairman of the Board. Mr. Knox was first appointed as a Non-executive Director of the Company on July 1, 2013.

Mr. Knox was formerly the Chief Executive Officer of United Healthcare of Pennsylvania, a division of United Healthcare, Inc., the largest health insurance provider in the world. Prior to this, Mr. Knox was Chairman of the Board and Chief Executive Officer of Fidelity Insurance Group, Inc., a life and health insurance provider.

Mr Knox is currently the Chief Executive Officer of Knox Consulting Group, an advisory and investment firm. In 2007, Mr. Knox stood as a candidate for Mayor of Philadelphia; and was a candidate for Governor of Pennsylvania from 2008 to 2010. His appointment as Co-chairman reflects Mr. Knox's position as a senior non-executive director of the Company.

"Thomas Knox is an extremely valuable member of the Board of Directors of Akers; he is a great supporter of the Company; and a major investor," said Raymond F. Akers Jr., Ph.D, Executive Co-chairman. "His connections and expertise in healthcare and finance are becoming ever more beneficial to Akers as we place greater emphasis on the commercialization strategy," added Dr. Akers. "I am honored to share the chairmanship of the Board with him."

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Raymond F. Akers, Jr. PhD

Executive Co-chairman of the Board

Akers Biosciences, Inc.

Tel. +1 856 848 8698

Twitter. @AkersBio

Emma Earl / Harrison Clarke

Daniel Stewart (Nomad and Broker)

Tel. +44 (0)20 7776 6550

Ben Simons / Alexandra Roper

Vigo Communications (UK Investor Relations)

Tel. +44 (0)20 7016 9570

Email. [email protected]

Brendan Hopkins

RedChip Companies, Inc. (US Investor Relations)

Tel. +1 407 644 4256 x134